STAT July 18, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today, we discuss the latest with Novartis — the company reported earnings today and fielded questions about the myelofibrosis drug it got through buying MorphoSys.
Novartis hedges on filing plans for MorphoSys drug
From my colleague Drew Joseph: Last year, when MorphoSys announced Phase 3 data for its experimental myelofibrosis drug, it said it planned to file for approval for the medicine, called pelabresib. And in February, when Novartis announced it was buying MorphoSys for nearly $3 billion, the Swiss pharma giant said it planned to submit the drug to the FDA this year.
But...
Today's Sponsors
Today's Sponsor